Jump to content

Here are the top-performing technology stocks of 2021


MongiIG

Recommended Posts

image.png

image.png

image.png

Technology stocks have been far from a sure bet since 2021 began its stretch run in mid-November. Inflationary concerns and fears of rising interest rates pushed investors out of software and internet companies, sending scores of prior outperformers into correction territory.

Despite the sell-off and the volatility across wide swaths of the tech industry, investors have made a bundle of money betting on specific companies and stories. Certain areas of the semiconductor market ballooned this year, as demand soared for processors that could speed crypto mining, aid game development and connect more devices to the internet.

 

Fintech, cloud software and cybersecurity had their share of standouts as well, even if buying baskets of those stocks and holding them for the year would not have been a particularly lucrative investment.

Here are the five biggest gainers in 2021 among U.S. tech companies valued at $5 billion or more. The list excludes companies that went public this year. Prices are as of Thursday’s close. CNBC

image.png

Link to comment
15 hours ago, Dandeli said:

How about Quest Diagnostics and Labcorp?

Hi @Dandeli

Thanks for reaching out.

image.png

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Quest reimagines diagnostics - Interbrand

 

Here are three of the most important factors that make the stock of this medical laboratory operator a great growth pick right now.

 

Earnings Growth

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Quest Diagnostics is 22.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.8% this year, crushing the industry average, which calls for EPS growth of 14.6%.

Impressive Asset Utilization Ratio

Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.

 

Right now, Quest Diagnostics has an S/TA ratio of 0.81, which means that the company gets $0.81 in sales for each dollar in assets. Comparing this to the industry average of 0.78, it can be said that the company is more efficient.

In addition to efficiency in generating sales, sales growth plays an important role. And Quest Diagnostics is well positioned from a sales growth perspective too. The company's sales are expected to grow 11% this year versus the industry average of 10.5%.

Promising Earnings Estimate Revisions

Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Quest Diagnostics have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.6% over the past month.

Bottom Line

Quest Diagnostics has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

For more on this article: entrepreneur.com

Link to comment
5 minutes ago, MongiIG said:

Hi @Dandeli

Thanks for reaching out.

image.png

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Quest reimagines diagnostics - Interbrand

 

Here are three of the most important factors that make the stock of this medical laboratory operator a great growth pick right now.

 

Earnings Growth

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Quest Diagnostics is 22.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.8% this year, crushing the industry average, which calls for EPS growth of 14.6%.

Impressive Asset Utilization Ratio

Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.

 

Right now, Quest Diagnostics has an S/TA ratio of 0.81, which means that the company gets $0.81 in sales for each dollar in assets. Comparing this to the industry average of 0.78, it can be said that the company is more efficient.

In addition to efficiency in generating sales, sales growth plays an important role. And Quest Diagnostics is well positioned from a sales growth perspective too. The company's sales are expected to grow 11% this year versus the industry average of 10.5%.

Promising Earnings Estimate Revisions

Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Quest Diagnostics have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.6% over the past month.

Bottom Line

Quest Diagnostics has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

For more on this article: entrepreneur.com

image.png

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Quest Diagnostics (DGX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

More on this article: nasdaq.com

Brand New: New Logo and Identity for Quest Diagnostics by InterbrandHealth

Link to comment
15 hours ago, Dandeli said:

How about Quest Diagnostics and Labcorp?

Hi @Dandeli

Thanks for reaching out.

image.png

Labcorp Jobs and Company Culture

Global life sciences company Laboratory Corporation of America Holdings (NYSE: LH), popularly known as Labcorp, entered into a definitive agreement to acquire cancer genomics solutions provider, Personal Genome Diagnostics Inc. for $575 million. The deal is likely to close in the first half of 2022.

Following the news, shares of the company declined marginally to close at $301.91 during yesterday’s extended trading session.

Terms of the Deal

Under the terms of the deal, Labcorp will initially pay $450 million in cash and an additional $125 million, subject to the achievement of certain milestones.

Strategic Impact

With this acquisition, Labcorp will gain access to Personal Genome’s advanced cancer genomics technology and subsequently gain a strong foothold in the space. Along with its existing liquid biopsy capabilities, Labcorp’s oncology portfolio will also receive a boost resulting in enhanced offerings for its patients.

Financial Implications of the Deal

Personal Genome is expected to register revenues of about $22 million in 2021 and about $40 million in 2022. Taking this into account, Labcorp expects the acquisition to be slightly dilutive to Labcorp’s adjusted earnings per share over the next couple of years. However, the acquisition will provide returns in excess of its cost of capital by year five.

Management Commentary

CEO of Labcorp, Adam Schechter, said "PGDx’s comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology. PGDx’s technology is well positioned in an important segment with strong growth prospects.”

Analyst Ratings

Recently, Mizuho Securities analyst Ann Hynes reiterated a Buy rating on the stock. The analyst, however, raised the price target from $332 to $354, which implies upside potential of 17.3% from current levels.

Wall Street Analysts Ratings is a Strong Buy based on 7 Buys and 1 Hold. The average Labcorp stock price prediction price target of $353.13 implies upside potential of 16.97% from current levels. Shares have gained 48.1% over the past year.

LH-1024x346.jpg

nasdaq.com

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      21,242
    • Total Posts
      90,842
    • Total Members
      41,344
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    ZerpSter
    Joined 03/02/23 12:24
  • Posts

    • Charting the Markets: 3 February S&P 500, Nasdaq 100 and Dow rally ahead of US non-farm payrolls. EUR/USD, GBP/USD and USD/JPY head lower after central bank volatility. And gold, oil and coffee prices drop back. Axel Rudolph FSTA | Senior Financial Analyst, London | Publication date: Friday 03 February 2023             This is here for you to catch up but if you have any ideas on markets or events you want us to relay to the TV team we’re more than happy to.
    • Gold, oil and coffee prices drop back Commodity prices received a knock as the dollar strengthened, pushing gold and coffee back from multi-month highs while oil’s decline continued. Source: Bloomberg      Chris Beauchamp | Chief Market Analyst, London | Publication date: Friday 03 February 2023  Gold drops back from $1950 Gold’s exuberance was checked on Thursday, with the price reversing from the nine-month high. Perhaps this now points towards a move lower in the short-term that may result in a higher low. For this the price will need to breach $1900, which provided support on Tuesday and earlier in January. A first destination for this would be the $1870 area, followed up by the 50-day simple moving average (SMA). Source: ProRealTime WTI slump pushes lower The price continued to decline on Thursday, falling to a three-week low. It continues to look like a lower high was made in the second half of January around $82 and the 100-day SMA. A continued decline, backed up by a falling daily MACD, suggests a move back to the January low at $73.40 and then on to the December low just above $70 is now possible. A reversal back above $79 would be needed to suggest another attempt to clear the 100-day SMA and then the $82 level is developing. Source: ProRealTime Coffee weakens after big run higher Coffee’s huge rally off the January lows suffered a severe check this week, though the price is holding above the 200-day SMA for now. This may be the lower high that sellers have been looking for, if they think that the post-December 2021 downtrend is still intact, a view supported by the declining 200-day SMA. A similar bounce in July and August then reversed course, which might provide a hope of a new decline. Additional gains would target 2160, and then to 2300+, the August 2022 peak. Source: ProRealTime
    • Tech earnings on Wednesday dented what was otherwise a party on Wall Street, with the S&P 500 and Nasdaq both going into bull market.  Jeremy Naylor | Writer, London | Publication date: Friday 03 February 2023  Apple, Amazon, and Alphabet injected a dose of realism about the headwinds, with Amazon forecasting that the current quarter could see flat operating income.   Tech stocks disappoint Apple, Amazon and Alphabet dented what was otherwise a party on tech stocks on Wall Street late on Thursday. Let's take a look at the earnings that we got from those big three tech companies. We begin first with Apple on its fiscal first quarter (Q1) earnings, posting numbers of $1.88 per share, a 10.9% drop compared to the same quarter last year. Analysts expected a $1.94. Revenues falling by 5.5%. In the detail iPhone and iMac revenue came in short of estimates, down 8.2% and 28.6% respectively. iPad revenue did rise 29%. Chief executive Tim Cook said three factors impacted the results: a strong dollar, production issues in China affecting iPhones, and the overall macroeconomic environment. Apple share price chart Let's take a look at the share price chart. And I think I want to do a daily candle here to begin with. You can see quite clearly the really long legs of this candle here indicate that the market initially took it as a positive going past the 200-day moving average and then came the pullback. But I think it's easier to see this if you look at it in 30-minute candles. We can quite clearly see the beginning of all-sessions trade and where we closed out down 3.48%. Amazon share price chart Amazon saw the same sort of thing. Shares were jittery in extended trade last night. The internet giant missed earnings estimates posting earnings per share (EPS) of $0.03 compared to $0.17 forecast. Revenue was better than expected at $149.2 billion. Investors were taken aback by the group's guidance. Amazon said its operating profit could fall to zero in the current quarter, as savings from layoffs don't make up for the financial impact of consumers and cloud customers clamping down on spending. Amazon forecast it earned between nothing and $4 billion in operating income this quarter, compared with the $4.04 billion that analysts had been expecting from the company. And Amazon believes sales growth in its long-lucrative cloud business will slow over the next few quarters as well. Let's take a look at the 30-minute chart for Amazon at the point at which it went into extended trade last night. Like Apple, it went up and then pulled back and we lost 5.07% in extended trade last night. Alphabet share price chart Meanwhile, Google owner Alphabet missed on both top and bottom lines for its fourth quarter (Q4) numbers. Google's parent company posted earnings of $1.05 a share on revenues of $76 billion. Analysts anticipated earnings per share of $1.18 on $76.5 billion in revenue. Alphabet suffered from a pullback in advertising revenue. Advertisers have cut their budgets of rising inflation and interest rates, fueled by concerns over consumer spending. The company said it would take a charge of between $1.9 billion and $2.3 billion, mostly in the first quarter of 2023, related to the layoffs of 12,000 employees announced back in January. And like all the big tech stocks last night, losing a lot of ground, initially rising all-sessions on the platform last night, and then came this pullback, ending down 4.9% at the end of extended trade.
×
×
  • Create New...